SalaryGuide
SalariesCompaniesJobs
AboutPricingBlog
For Employers

Marketing jobs

1 marketing jobs

Penumbra, Inc. logo
1 day ago

Neurovascular Product Marketing Specialist T

Penumbra, Inc.

Alameda, CA (Unknown)$20/hr – $30/hr

Jobs by location

  • California
  • New York
  • Illinois
  • Texas
  • Massachusetts
  • Florida
  • New Jersey
  • Colorado
  • Washington
  • Virginia
  • Pennsylvania
  • Minnesota

Marketing jobs in the US

Marketing jobs in the US

1 jobs
Penumbra, Inc. logo

Neurovascular Product Marketing Specialist T

Penumbra, Inc.

Alameda, CA (Unknown)

$20/hr - $30/hrIn-houseMid level1+ years exp.
1 day ago
Penumbra, Inc. logo
Penumbra, Inc.

Neurovascular Product Marketing Specialist T

Alameda, CA (Unknown)

$20/hr – $30/hrMid Level1+ years exp

Posted 1 day ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • Company news
  • Links

Job Summary

Own the end-to-end support for clinical literature development and sales tools, drive cross-functional collaboration, and lead small strategic projects from concept to delivery.

  • Coordinate data gathering for publications and presentations
  • Translate field feedback into usable materials and interfaces

Job Description

Responsibilities

  • Provide administrative support for the development and production of new marketing literature and sales support tools, specifically as they relate to clinical literature.
  • Participate in clinical data gathering and review activities, identifying major studies, key end points, upcoming trials, and data release dates (PEN and competitive products) to support publications and scientific presentations that underpin Penumbra’s messages and clinical value propositions in the medical community.
  • Spearhead special projects such as new website and app development
  • Conduct qualitative and quantitative research with field representatives to understand pain points and develop material and interface functionalities that meet their needs.
  • Work closely with cross-functional teams (clinical affairs, regulatory, legal, IT, data privacy) to ensure there is alignment on material output.
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures.
  • Understand relevant security, privacy, and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company.
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures.
  • Perform other work-related duties as assigned.

Requirements

  • Bachelor’s degree with 1+ years of business, administrative, or marketing experience, or equivalent combination of education and experience.

Preferred

  • Coursework in biology, neuroscience, business, or related discipline.
  • Proficiency with Word, PowerPoint, Excel, and other standard office tools required.
  • Strong oral, written, and interpersonal communication skills required.
  • High degree of accuracy and attention to detail.
  • Some exposure to digital marketing.

Benefits

  • A collaborative teamwork environment where learning is constant, and performance is rewarded.
  • The opportunity to be part of the team that is revolutionizing the treatment of some of the world's most devastating diseases.
  • A generous benefits package for eligible employees that includes medical, dental, vision, life, AD&D, short and long-term disability insurance, 401(k) with employer match, paid parental leave, eleven paid company holidays per year, a minimum of fifteen days of accrued vacation per year, which increases with tenure, and paid sick time in compliance with applicable law(s).
Penumbra, Inc. logo

Penumbra, Inc.

3.1 Glassdoor

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. Members of the Penumbra team agree that this is where their work has meaning -- we are transforming the treatment of some of the world's most devastating conditions. Penumbra is where everyone's ideas matter, and where learning and growth are constant.No. 5 on the Greater Bay Area Manufacturers List, San Francisco Business Times, 2020100 Fastest-Growing Companies, Fortune, 2019Review our community guidelines for LinkedIn here: https://bit.ly/2Jmbw83.

Founded in 2004
Alameda, California, USA
2.9K employees (140 in marketing)
www.penumbrainc.com
53% recommend to a friend
68% CEO approval

Salaries

Posted range

$20/hr – $30/hr

Taken straight from the job posting.

See all Penumbra, Inc. salaries

Marketing Team

Marketing Team Size
121 (4% of company)
Median Tenure
3.6 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$2.9M
Last Raise
$2.7M
Post IPO Equity, 5 years ago

Funding History

  • Aug 2021
    Post IPO Equity • $2.7M
  • Nov 2012
    Seed • $121.2K

Traffic Signals

Monthly Visitors
46.4K
Traffic Source Mix
Search
54.2%
Direct
37.9%
Referral
5.6%
Social
1.2%
Paid
0.9%

Headcount Trend

Current headcount: ~2.9K

News about Penumbra, Inc.

Is Penumbra Inc. stock a top hedge fund pick - Share Buyback & Safe Entry Point Alerts
Nov 20, 2025 • newser.com
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 19, 2025 • Lelezard
Is Penumbra Inc. stock trading at attractive multiples - Recession Risk & Verified Entry Point Detection
Nov 19, 2025 • newser.com
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 19, 2025 • PR Newswire
Why retail traders accumulate Penumbra Inc. (0P8) stock - Market Growth Summary & Verified Entry Point Signals
Nov 19, 2025 • newser.com
Custom watchlist performance reports with Penumbra Inc. - Dip Buying & Long-Term Safe Investment Ideas
Nov 19, 2025 • newser.com
Is Penumbra Inc. stock a top hedge fund pick - Portfolio Risk Summary & Reliable Price Action Trade Plans
Nov 17, 2025 • newser.com
How supply shortages influence Penumbra Inc. stock - Trade Analysis Report & Growth Oriented Trade Recommendations
Nov 16, 2025 • newser.com
Why Penumbra (PEN) Is Up 5.3% After Raising 2025 Guidance and STORM-PE Trial Results
Nov 13, 2025 • simplywall.st
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN)
Nov 12, 2025 • GuruFocus
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
Nov 11, 2025 • Zacks Investment Research
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
Nov 11, 2025 • Yahoo Finance
Do Options Traders Know Something About Penumbra Stock We Don't?
Nov 10, 2025 • Yahoo Finance
Penumbra, Inc. Just Recorded A 29% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 8, 2025 • Yahoo Finance
Penumbra price target raised to $355 from $350 at Canaccord
Nov 7, 2025 • Yahoo Finance
Insider Sell: Harpreet Grewal Sells Shares of Penumbra Inc (PEN)
Nov 6, 2025 • GuruFocus
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
Nov 5, 2025 • PR Newswire
Penumbra Inc (PEN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and New Product ...
Nov 5, 2025 • Yahoo Finance
Earnings Flash (PEN) Penumbra, Inc. Posts Q3 Adjusted EPS $0.97 per Share, vs. FactSet Est of $0.93
Nov 5, 2025 • MarketScreener
Penumbra Inc earnings beat by $0.04, revenue topped estimates
Nov 5, 2025 • investing.com
Penumbra, Inc. Reports Strong Q3 2025 Growth
Nov 5, 2025 • TipRanks
Penumbra Inc (PEN) Q3 2025 Earnings: EPS of $1.17 Beats Estimate, Revenue Surges to $354.7 Million
Nov 5, 2025 • GuruFocus
More data supports Penumbra mechanical thrombectomy system
Nov 4, 2025 • MassDevice
Penumbra (NYSE: PEN) Reports 472m vs 376m six-minute walk gains with CAVT in STORM-PE
Nov 3, 2025 • Stock Titan
What To Expect From Penumbra’s (PEN) Q3 Earnings
Nov 3, 2025 • Yahoo Finance
Penumbra’s thrombectomy treatment shows better outcomes for PE patients
Nov 3, 2025 • investing.com
Is Penumbra’s Stock Still a Good Bet After a 7% Drop in the Past Month?
Oct 29, 2025 • Yahoo Finance
Why Penumbra (PEN) Shares Are Falling Today
Oct 28, 2025 • Yahoo Finance
Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings)
Oct 27, 2025 • Benzinga
Penumbra Inc. Launches i-RISE Study to Enhance Stroke Treatment Insights
Oct 27, 2025 • TipRanks
Penumbra’s thrombectomy system shows superior results for PE patients
Oct 27, 2025 • investing.com
Penumbra (NYSE: PEN) RCT: CAVT 78.3% positive effect vs 51.9% with anticoagulation
Oct 27, 2025 • Stock Titan
Penumbra takes TCT by STORM
Oct 27, 2025 • BioWorld MedTech
Penumbra study backs mechanical thrombectomy for treating pulmonary embolism
Oct 27, 2025 • MassDevice
Is Penumbra Inc. (0P8) stock a momentum leader - Analyst Upgrade & AI Based Buy and Sell Signals
Oct 24, 2025 • newser.com
Why Penumbra Inc. stock is a strong buy call - 2025 Performance Recap & Fast Momentum Entry Tips
Oct 24, 2025 • newser.com
Why Penumbra Inc. (0P8) stock is a strong buy call - Weekly Trend Report & Safe Capital Growth Plans
Oct 23, 2025 • newser.com
How Penumbra became a $1 billion leader in blood clot removal devices - San Francisco Business Times
Oct 23, 2025 • The Business Journals
Does Penumbra Inc. stock trade at a discount to peers - Weekly Stock Recap & Accurate Entry/Exit Alerts
Oct 23, 2025 • newser.com
Is Penumbra Inc. (0P8) stock a momentum leader - July 2025 Market Mood & Daily Oversold Stock Bounce Ideas
Oct 23, 2025 • newser.com
How Investors Are Reacting To Penumbra (PEN) Upgrade on Thunderbolt's Growth Potential and Margin Expansion
Oct 23, 2025 • simplywall.st
Is Penumbra Inc. (0P8) stock a momentum leader - Market Risk Analysis & Growth Focused Entry Reports
Oct 22, 2025 • newser.com
Applying Elliott Wave Theory to Penumbra Inc. - Insider Buying & Safe Capital Investment Plans
Oct 21, 2025 • newser.com
Will Penumbra Inc. (0P8) stock sustain bullish trend into 2025 - 2025 Year in Review & Smart Money Movement Tracker
Oct 21, 2025 • newser.com
How Penumbra Inc. stock responds to policy changes - 2025 Institutional Moves & Long Hold Capital Preservation Plans
Oct 21, 2025 • newser.com
Is Penumbra Inc. (0P8) stock a momentum leader - 2025 Big Picture & High Win Rate Trade Alerts
Oct 21, 2025 • newser.com
Custom watchlist performance reports with Penumbra Inc. - 2025 Market Sentiment & Consistent Income Trade Ideas
Oct 20, 2025 • newser.com
Why Penumbra Inc. (0P8) stock is a strong buy call - Global Markets & High Conviction Trade Alerts
Oct 20, 2025 • newser.com
Needham Upgrades Penumbra (PEN) to Buy Amid 2026 Growth Outlook
Oct 20, 2025 • Insider Monkey
Needham Upgrades Penumbra (PEN) to Buy Amid 2026 Growth Outlook
Oct 20, 2025 • Yahoo Finance
Predicting Penumbra Inc. trend using moving averages - Market Growth Report & Pattern Based Trade Signal System
Oct 20, 2025 • newser.com
Portfolio Recap: What earnings margins imply for Penumbra Inc. (0P8) stock - Trade Performance Summary & Stock Market Timing Techniques
Oct 20, 2025 • nchmf.gov.vn
Needham Upgrades Penumbra (PEN) to Buy Amid 2026 Growth Outlook
Oct 20, 2025 • Insider Monkey
Does Penumbra Inc. stock trade at a discount to peers - July 2025 Patterns & Real-Time Volume Trigger Notifications
Oct 20, 2025 • newser.com
Risk Recap: How Penumbra Inc. stock responds to policy changes - Stop Loss & Weekly Watchlist for Hot Stocks
Oct 18, 2025 • nchmf.gov.vn
Penumbra (PEN): Evaluating Valuation After Needham Upgrade and 2026 Growth Catalysts
Oct 13, 2025 • Yahoo Finance
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Oct 9, 2025 • BioSpace
Penumbra upgraded at Needham on revenue growth acceleration
Oct 8, 2025 • Seeking Alpha
Needham Upgrades Penumbra (PEN) to 'Buy' with New Price Target o
Oct 8, 2025 • GuruFocus
Oct 26 Investor Event — Penumbra Hosts TCT Presentation; Earnings Release Nov 5
Oct 8, 2025 • Stock Titan
Penumbra (PEN) Stock Trades Up, Here Is Why
Oct 8, 2025 • Yahoo Finance
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 – Company Announcement - FT.com
Oct 8, 2025 • Financial Times
What Makes Penumbra (PEN) a Good Investment?
Sep 18, 2025 • Yahoo Finance
Interventional Neurology Devices Market Poised for Transformative Growth with Rising Stroke & Aneurysm Treatments 2025
Sep 12, 2025 • EIN Presswire
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile
Sep 9, 2025 • PR Newswire
Daily Digest: Anthropic gets funding while OpenAI sells shares and makes an acquisition
Sep 3, 2025 • Seattle TechFlash
This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Sep 2, 2025 • Benzinga.com
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2
Aug 27, 2025 • Yahoo Finance
Penumbra, Inc. Names Shruthi Narayan as Company President
Aug 27, 2025 • PR Newswire
Penumbra promotes from within to fill president position
Aug 27, 2025 • MassDevice
Penumbra, Inc. Names Shruthi Narayan as Company President
Aug 27, 2025 • PR Newswire
Penumbra Appoints Shruthi Narayan as President
Aug 27, 2025 • MarketScreener
Penumbra, Inc. (PEN): A Bull Case Theory
Aug 26, 2025 • Yahoo Finance
Blood Clot Retrieval Devices Market Size and Growth Outlook
Aug 25, 2025 • PharmiWeb
Penumbra Insider Sold Shares Worth $4,046,952, According to a Recent SEC Filing
Aug 25, 2025 • MarketScreener
Penumbra CEO Adam Elsesser Sells Shares Worth Over $4 Million
Aug 22, 2025 • TradingView
Penumbra, Inc. to Present at Upcoming Investor Conferences – Company Announcement
Aug 20, 2025 • Financial Times
Healthcare Tech Leader Penumbra Scheduled for Wells Fargo and Morgan Stanley September Conferences
Aug 20, 2025 • Stock Titan
Penumbra, Inc. to Present at Upcoming Investor Conferences
Aug 20, 2025 • MarketScreener
Penumbra, Inc. to Present at Upcoming Investor Conferences
Aug 20, 2025 • PR Newswire
Clot Management Device Market is Set to Grow at an Impressive CAGR of 6.35% Through 2035 | USD 7.5 Billion
Aug 13, 2025 • EIN Presswire
Neurointerventional Device Market is Forecasted to Reach USD 6.49 Billion By 2034, at an Impressive 7.43% CAGR
Aug 13, 2025 • EIN Presswire
Neurovascular Thrombectomy Device Market is Poised to Growth USD 4.5 Billion by 2035 with Thriving CAGR of 5.54%
Aug 12, 2025 • EIN Presswire
Transcript : Penumbra, Inc. Presents at Canaccord Genuity?s 45th Annual Growth Conference, Aug-12-2025 12
Aug 12, 2025 • MarketScreener
Neurothrombectomy Device Market is Poised to Growth USD 4.0 Billion by 2035 with Thriving CAGR of 6.32%
Aug 11, 2025 • EIN Presswire
Transcatheter Embolization And Occlusion Devices Market Growth Trends, Competitive Strategies and Forecasts, 2025-2033
Aug 6, 2025 • Research and Markets
Penumbra PEN Q2 2025 Earnings Call Transcript
Aug 4, 2025 • The Motley Fool
Should You Invest in Penumbra (PEN)?
Jul 31, 2025 • Insider Monkey
US stock market futures edge higher today as Wall Street stays in ‘wait and see’ mode ahead of Fed decision, Microsoft and Meta earnings in high-stakes trading showdown
Jul 30, 2025 • IndiaTimes
Thrombectomy Devices Market to Reach $2.31B by 2031, Fueled by Stroke Burden and Tech Innovation
Jul 30, 2025 • EIN Presswire
Penumbra Shares Rise After Q2 Results Beat
Jul 30, 2025 • MarketScreener
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
Jul 30, 2025 • BioSpace
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025 • PR Newswire
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025 • Morningstar.com
PENUMBRA Earnings Results: $PEN Reports Quarterly Earnings
Jul 29, 2025 • Quiver Quantitative
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
Jul 29, 2025 • TradingView
Penumbra, Inc. Reports Strong Q2 2025 Results
Jul 29, 2025 • TipRanks
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
Jul 29, 2025 • PR Newswire
Transcript : Penumbra, Inc., Q2 2025 Earnings Call, Jul 29, 2025
Jul 29, 2025 • MarketScreener
Five years after COVID, pharma shares languish in U.S. policy limbo
Jul 23, 2025 • BNN Bloomberg

Links

www.penumbrainc.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.